achillestx.com (ACHL): Net earnings per share growth forecast for next year

Public company logo of Achilles Therapeutics plc (ACHL)

Achilles Therapeutics is developing personalized T-cell therapy leveraging PELEUS platform data and bioprinting patents. This GURU.Markets consensus EPS n+1 forecast chart illustrates the current trend, with the latest data point standing at 33.40. High margins on customized solutions offset scaling challenges, while the massive neoantigen market provides significant opportunities to expand the company's partner network.

Achilles Therapeutics (ACHL): Net earnings per share growth forecast for next year from 07/04/2022 to 03/29/2025

Summary analytical data breakdowns for Achilles Therapeutics PLC (ACHL)

- share price and consensus valuation forecast:
Fundamental company analysis:ACHL, Achilles Tx
Finished products of Achilles Therapeutics plc

For Achilles Therapeutics (ACHL), which is developing personalized cell therapy through scientific collaborations, the trends in the company's EPS forecasts for the coming year reflect the market's valuation of the commercialization of its developments. The dynamics of this metric are based on analysts' consensus expectations for net earnings per share, where sharp deviations in the line signal a revision of the business's fundamental value and risks of a significant price correction.